Trial
NCT02635061
Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Celgene
Collaborators
—
Condition
Non Small Cell Lung Cancer
Intervention
ACY-241
Why stopped
Lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-05-07